Key result
Restarting OAC post-ICH cuts ischemic stroke risk ~80% but increases recurrent hemorrhage.
Why the study?
Resuming oral anticoagulation in patients with AF after intracranial hemorrhage is clinically challenging due to competing risks of ischemic stroke and recurrent bleeding.
Does restarting oral anticoagulation reduce ischemic stroke and affect recurrent bleeding in patients with atrial fibrillation following an intracranial hemorrhage?
Does restarting oral anticoagulation reduce ischemic stroke and affect recurrent bleeding in patients with atrial fibrillation following an intracranial hemorrhage?
In patients with atrial fibrillation and prior intracranial hemorrhage, resuming oral anticoagulation reduces ischemic stroke risk but significantly increases recurrent intracranial hemorrhage and major bleeding without improving survival.
Informs individualized resumption decisions balancing ischemic stroke reduction against recurrent hemorrhage in AF post-ICH; strengthens RCT evidence on net trade-offs.
Background: The decision to resume oral anticoagulation in patients with atrial fibrillation after an intracranial hemorrhage remains a significant clinical challenge due to competing risks of ischemic stroke and recurrent bleeding. Objective: To evaluate the benefits and risks of restarting oral anticoagulation in patients with atrial fibrillation who have experienced a spontaneous intracranial hemorrhage. Methods: We conducted a systematic review and meta-analysis of randomized controlled trials comparing long-term use of any oral anticoagulant to no anticoagulation (placebo, standard care, or open control) in patients with atrial fibrillation following an intracranial hemorrhage. We searched MEDLINE (PubMed), Embase, CENTRAL, ClinicalTrials.gov, WHO ICTRP, EUCTR, and grey literature through March 2025. The primary outcomes were ischemic stroke and recurrent intracranial hemorrhage. Secondary outcomes included major adverse cardiovascular events, major bleeding, cardiovascular mortality, and all-cause mortality. Risk ratios (RRs) with 95% confidence intervals (CIs) were pooled using standard meta-analytic techniques. Results: Five randomized controlled trials with a total of 733 patients were included. Compared to no anticoagulation, restarting oral anticoagulation significantly reduced the risk of ischemic stroke (RR 0.20; 95% CI: 0.05–0.75) and major adverse cardiovascular events (RR 0.59; 95% CI: 0.37–0.94). However, it was associated with increased risks of recurrent intracranial hemorrhage (RR 3.51; 95% CI: 1.50–8.22) and major bleeding (RR 2.22; 95% CI: 1.06–4.62). There were no significant differences in cardiovascular mortality (RR 1.00; 95% CI: 0.44–2.28) or all-cause mortality (RR 0.94; 95% CI: 0.65–1.37). Conclusions: In patients with atrial fibrillation who have survived an intracranial hemorrhage, resuming oral anticoagulation appears to significantly reduce the risks of ischemic stroke and major cardiovascular events, but increases the likelihood of recurrent hemorrhage and major bleeding. No survival benefit was observed. These findings highlight the need for individualized decision-making based on patient-specific risk profiles.
No takes yet. Share an insight, caveat, or question.
Vats et al. (2026) studied this question. Restarting oral anticoagulation post-intracranial hemorrhage significantly reduced ischemic stroke risk (RR 0.20) but increased recurrent hemorrhage risk (RR 3.51).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: